MIRVASO topical gel is an alpha adrenergic agonist intended for topical treatment of moderate to severe rosacea.

**Contraindications**

- **Hypersensitivity**: Do not use in patients with a history of hypersensitivity to any component of MIRVASO, including brimonidine.
- **Severe Cardiovascular Disease**: Do not use in patients with severe or unstable or uncontrolled cardiovascular disease.
- **Potentiation of Vascular Insufficiency**: Do not use in patients with Raynaud's phenomenon, orthostatic hypotension, thrombangiitis obliterans, scleroderma, or Sjögren's syndrome.

**Warnings and Precautions**

- **Local Vasomotor Adverse Reactions**: Some subjects in the clinical trials discontinued use of MIRVASO topical gel because of erythema.
- **Systemic Adverse Reactions**: Flushing may occur during or after administration of MIRVASO topical gel.
- **Laboratory Test Changes**: If necessary, blood pressure should be measured during treatment and prior to discontinuation.
- **Drug Interactions**: Specific drug-drug interaction studies have not been conducted with MIRVASO topical gel.

**Adverse Reactions**

- **Systemic Adverse Reactions**: Flushing may occur during or after administration of MIRVASO topical gel.
- **Local Vasomotor Adverse Reactions**: Some subjects in the clinical trials discontinued use of MIRVASO topical gel because of erythema.
- **Systemic Adverse Reactions**: Flushing may occur during or after administration of MIRVASO topical gel.
- **Laboratory Test Changes**: If necessary, blood pressure should be measured during treatment and prior to discontinuation.
- **Drug Interactions**: Specific drug-drug interaction studies have not been conducted with MIRVASO topical gel.
MIRVASO topical gel did not include sufficient numbers of subjects aged 65 and over to determine whether they respond.

Brimonidine is a relatively selective alpha-2 adrenergic agonist. Topical application of MIRVASO topical gel may reduce erythema through direct vasoconstriction. The molecular formula of brimonidine tartrate is C_{29}H_{27}BrN_{2}O_{5}. Brimonidine tartrate has a molecular weight of 442.24 and appears as white to slightly yellowish powder. Chemically, brimonidine tartrate is 5-Bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate. Brimonidine tartrate has an oral bioavailability of approximately 10%.

Oral overdoses of other alpha-2 adrenergic agonists have been reported to cause symptoms such as hypotension, bradycardia, and cardiac arrest. There are no reports of deaths associated with brimonidine. In a 12-month dermal photo-carcinogenicity study, topical doses of 0% (MIRVASO topical gel vehicle), 0.18%, 1% and 2% brimonidine tartrate gel were administered to hairless albino mice once daily, five days per week, with concurrent exposure in females once daily for 24 months. No drug-related neoplasms were observed in this study. In a 21-month oral (diet) mouse carcinogenicity study and a 24-month oral (diet) rat carcinogenicity study, no drug-related neoplasms were observed in mice at oral doses of brimonidine tartrate up to 2.5 mg/kg/day or in rats at oral doses of brimonidine tartrate up to 25 mg/kg/day.

Nonclinical toxicology studies included a 52-week dermal phototoxicity study in female hairless albino mice at topical doses of 0% (vehicle), 0.18%, 1% and 2% brimonidine tartrate and an 8-week dermal carcinogenicity study in Sprague-Dawley rats at topical doses of 0% (vehicle), 0.18% and 1% brimonidine tartrate. No drug-related neoplasms were observed in this study.

Geriatric use: At the same dose level as younger adults, elderly patients may have a smaller skin surface area to body weight ratio, which may affect the systemic exposure to MIRVASO topical gel.

Onset of action: MIRVASO topical gel is administered once daily for 29 days. The onset of action is within 1 to 2 hours of the first application.

Duration of action: The duration of action is 27 days. The clinical improvement is maintained until the end of the daily application period. The efficacy was maintained after treatment for 29 days.

How to use MIRVASO topical gel:

1. Apply a pea-sized amount of MIRVASO topical gel onto each of the five areas of your face: forehead, chin, nose, and cheeks. Use the applicator to smoothly and evenly distribute the gel in a thin layer over your face. Avoid contact with your eyes and lips. Do not apply MIRVASO topical gel to irritated skin or open wounds. See "Important information" at the beginning of this Patient Information leaflet.

2. Smoothly rub the gel into your face until it is evenly distributed. Do not wash your face immediately after applying MIRVASO topical gel.

3. After applying MIRVASO topical gel, wash your hands.

Instructions for use of MIRVASO topical gel: